Compartir
array:18 [ "pii" => "13143256" "issn" => "02104806" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2009;33:609-14" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2657 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 1613 "PDF" => 1037 ] ] "itemAnterior" => array:14 [ "pii" => "13143257" "issn" => "02104806" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2009;33:603-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3918 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 1487 "PDF" => 2422 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Recidiva local del tumor renal" "tienePdf" => array:2 [ 0 => "es" 1 => "en" ] "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "603" "paginaFinal" => "608" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:2 [ "es" => true "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Emilio García Galisteo, P. Morales Jiménez, D. Hernández Alcaraz, Víctor Baena González" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Emilio" "apellidos" => "García Galisteo" ] 1 => array:2 [ "Iniciales" => "P." "apellidos" => "Morales Jiménez" ] 2 => array:2 [ "Iniciales" => "D." "apellidos" => "Hernández Alcaraz" ] 3 => array:2 [ "nombre" => "Víctor" "apellidos" => "Baena González" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13143257?idApp=UINPBA00004N" "url" => "/02104806/0000003300000005/v0_201607111116/13143257/v0_201607111120/es/main.assets" ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Nuevas terapias de diana celular: indicaciones, resultados ytolerabilidad" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "609" "paginaFinal" => "614" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Joaquim Bellmunt, Antoni Gelabert-Mas" "autores" => array:2 [ 0 => array:3 [ "nombre" => "Joaquim" "apellidos" => "Bellmunt" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "Antoni" "apellidos" => "Gelabert-Mas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Oncología Médica (GU y GI)." "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Servicio y Cátedra de Urología. Hospital del Mar. Barcelona, España" "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "pdfFichero" => "292v33n05a13143256pdf001.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec689524" "palabras" => array:1 [ 0 => "Cáncer renal metastásico, Terapia diana celular, Sunitinib, Sorafenib,Temsirolimus, Overolimus" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec689525" "palabras" => array:6 [ 0 => "Metastatic renal cancer" 1 => "Cell targeted therapy" 2 => "Sunitinib" 3 => "Sorafenib" 4 => "Temsirolimus" 5 => "Overolimus" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "Los avances en la comprensión de la biologíamolecular del RCC ha dado lugar al desarrollo detratamientos biológicos dirigidos (terapias diana)que representan, por vez primera en más de quinceaños de tan solo disponer de las citocinas comoarma terapéutica, un avance significativo en el tratamientode esta enfermedad, con una mejoraimportante en la supervivencia libre de enfermedady con algunos fármacos, de la supervivencia global.Asimismo, el perfil de toxicidad con respecto a lostratamientos considerados estándar como las citoquinashan mejorado de forma ostensible." ] "en" => array:1 [ "resumen" => "Advances in understanding of the molecular biology of RCC have led to development of targeted biological treatments (targeted therapies) which, after more than 15 years in which the only therapeutic weapons available were cytokines, represent a significant advance in the treatment of this disease, resulting in a significant improvement in disease-free survival and, with some drugs, in overall survival. The toxicity profile has also markedly improved as compared to standard treatments such as cytokines." ] ] ] "idiomaDefecto" => "es" "url" => "/02104806/0000003300000005/v0_201607111116/13143256/v0_201607111120/es/main.assets" "Apartado" => array:4 [ "identificador" => "55588" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Original" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02104806/0000003300000005/v0_201607111116/13143256/v0_201607111120/es/292v33n05a13143256pdf001.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13143256?idApp=UINPBA00004N" "pdfAlternativo" => array:1 [ 0 => array:3 [ "idioma" => "en" "documentoPdf" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/file/02104806/addon/13143256/S300/en/292v33n05a13143256pdf001_2.pdf" "portada" => "292v33n05a13143256pdf001_2.png" ] ] ]
